Amy Langan, Vice President of Marketing and Business Development, announced that PharMEDium will highlight its enhanced labeling for sterile intravenous compounded ICU Services at the National Teaching Institute (NTI) and Critical Care Exposition, May 19-24, 2012 in Orlando, Florida.
Ms. Langan invites critical care professionals to visit Booth #2668 to see how the enhanced labels help clinicians and pharmacy staff with easier drug and dose recognition when stocking, retrieving, and administering compounded services from PharMEDium. Onsite PharMEDium associates will showcase the functionality and appearance of the enhanced labels and packaging, which are resultant of PharMEDium's ongoing commitment to patient safety, quality and innovation.
"Attendees at the NTI and Critical Care Exposition anticipate seeing new ideas, approaches and innovations designed to help them provide patient safety and quality of care for critically ill patients," stated David N. Jonas, CEO and Chairman of the Board. "As the key educational and informational event for critical care caregivers, this meeting is an ideal forum for PharMEDium to present our new and enhanced labeling for ICU services."
At the 2011 Chicago exposition, PharMEDium conducted market research with over 1000 critical care nurses, enabling PharMEDium to gain a broader understanding of the medication administration challenges critical care nurses face. The findings were the foundation for several of the enhancements now in the market. For example, service being delivered with new labels includes Phenylephrine, Norepinephrine and Vasopressin ready-to-use compounded sterile preparations. David N. Jonas, PharMEDium Chairman and CEO, added, "We have received positive feedback about the labeling enhancements. We're enthusiastic to be a part of this professional group and PharMEDium is proud to be a corporate sponsor of the American Association of Critical Care Nurses."
New machine learning model predicts cardiac arrest in ICU patients using ECG data with high accuracy